• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictive and prognostic significance of CD8 tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗的腔面B/HER 2阴性乳腺癌患者中CD8肿瘤浸润淋巴细胞的预测和预后意义
Oncol Lett. 2017 Jul;14(1):337-344. doi: 10.3892/ol.2017.6144. Epub 2017 May 10.
2
The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.新辅助化疗后手术治疗的非小细胞肺癌患者肿瘤浸润淋巴细胞的预后价值。
Adv Clin Exp Med. 2023 Aug;32(8):847-853. doi: 10.17219/acem/159242.
3
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.三阴性乳腺癌患者肿瘤浸润淋巴细胞的预后价值:系统评价和荟萃分析。
BMC Cancer. 2020 Mar 4;20(1):179. doi: 10.1186/s12885-020-6668-z.
4
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌新辅助化疗后残留肿瘤中肿瘤浸润性CD8 +和FOXP3 +淋巴细胞的预后意义及这些参数的变化:一项回顾性多中心研究
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
5
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.肿瘤浸润淋巴细胞预测雌激素受体阴性乳腺癌对蒽环类化疗的反应。
Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.
6
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.肿瘤浸润淋巴细胞与程序性死亡配体1表达在早期乳腺癌中的预后意义
Clin Breast Cancer. 2016 Feb;16(1):51-8. doi: 10.1016/j.clbc.2015.07.006. Epub 2015 Aug 6.
7
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.肿瘤浸润淋巴细胞在不同分子亚型乳腺癌患者中的预测和预后作用:一项荟萃分析。
BMC Cancer. 2020 Nov 25;20(1):1150. doi: 10.1186/s12885-020-07654-y.
8
Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.肿瘤浸润 CD8+T 细胞与肿瘤相关 CD68+巨噬细胞联合预测可切除胃癌的术后预后和辅助化疗获益。
BMC Cancer. 2019 Sep 14;19(1):920. doi: 10.1186/s12885-019-6089-z.
9
Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.新辅助化疗前后肿瘤浸润淋巴细胞与乳腺癌患者病理完全缓解及预后的关系。
Cancer Med. 2021 Nov;10(22):7921-7933. doi: 10.1002/cam4.4302. Epub 2021 Sep 25.
10
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗三阴性乳腺癌中肿瘤浸润淋巴细胞的预测和预后影响
Ecancermedicalscience. 2017 Aug 15;11:759. doi: 10.3332/ecancer.2017.759. eCollection 2017.

引用本文的文献

1
The interplay between the immune response and neoadjuvant therapy in breast cancer.乳腺癌中免疫反应与新辅助治疗之间的相互作用。
Front Oncol. 2025 May 12;15:1469982. doi: 10.3389/fonc.2025.1469982. eCollection 2025.
2
Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.可手术乳腺癌中CD8⁺肿瘤浸润淋巴细胞的预后意义:一项荟萃分析
BMC Cancer. 2025 Apr 2;25(1):601. doi: 10.1186/s12885-025-13912-8.
3
Immunoscore CD3/CD8 and FOXP3 Expression Correlate to Neoadjuvant Chemotherapy Response in Triple Negative Breast Cancer: A Case-Control Study.免疫评分CD3/CD8和FOXP3表达与三阴性乳腺癌新辅助化疗反应相关:一项病例对照研究
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):117-126. doi: 10.31557/APJCP.2025.26.1.117.
4
CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.乳腺癌中CD3 +肿瘤浸润淋巴细胞:其预后作用及与临床参数的关联
Cureus. 2024 Dec 10;16(12):e75479. doi: 10.7759/cureus.75479. eCollection 2024 Dec.
5
Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.浸润性乳腺癌新辅助化疗的反应可通过 CD4+、CD8+ 和 FOXP3+肿瘤浸润淋巴细胞预测。
Asian Pac J Cancer Prev. 2024 May 1;25(5):1607-1613. doi: 10.31557/APJCP.2024.25.5.1607.
6
Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence.利用人工智能评估腔面型乳腺癌中的肿瘤浸润淋巴细胞。
Br J Cancer. 2023 Nov;129(11):1747-1758. doi: 10.1038/s41416-023-02451-3. Epub 2023 Sep 30.
7
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.靶向谷氨酰胺代谢增强表皮生长因子受体驱动的肺癌免疫预防。
Adv Sci (Weinh). 2022 Sep;9(26):e2105885. doi: 10.1002/advs.202105885. Epub 2022 Jul 21.
8
Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.曲妥珠单抗和帕妥珠单抗新辅助双阻断治疗 HER2 基因扩增型乳腺癌的病理完全缓解预测。
Front Immunol. 2022 May 19;13:877825. doi: 10.3389/fimmu.2022.877825. eCollection 2022.
9
CD8+ TILS Expression in Invasive Breast Carcinoma (No Special Type).浸润性乳腺癌(非特殊型)中 CD8+ TILS 的表达。
Asian Pac J Cancer Prev. 2022 May 1;23(5):1813-1816. doi: 10.31557/APJCP.2022.23.5.1813.
10
The Prognostic Significance of MACC1 Expression in Breast Cancer and Its Relationship to Immune Cells in the Tumor Microenvironment and Patient Survival.MACC1 表达在乳腺癌中的预后意义及其与肿瘤微环境中免疫细胞和患者生存的关系。
Medicina (Kaunas). 2021 Sep 5;57(9):934. doi: 10.3390/medicina57090934.

本文引用的文献

1
A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.用于非小细胞肺癌的程序性死亡受体1(PD-1)检查点抑制剂的新成员——抗程序性死亡配体1(PD-L1)抗体MEDI4736。
Transl Lung Cancer Res. 2014 Dec;3(6):408-10. doi: 10.3978/j.issn.2218-6751.2014.11.10.
2
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.肿瘤浸润淋巴细胞(TILs)对预测乳腺癌新辅助化疗反应的价值:一项系统评价和荟萃分析
PLoS One. 2014 Dec 12;9(12):e115103. doi: 10.1371/journal.pone.0115103. eCollection 2014.
3
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.腔面 B 型乳腺癌:分子特征、临床管理及未来展望。
J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21.
4
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.CD8+T 细胞浸润与 12439 例乳腺癌患者生存的相关性。
Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.
5
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.多中心新辅助 II 期研究:帕尼单抗联合蒽环类/紫杉类化疗治疗可手术的三阴性乳腺癌:鉴定预测治疗效果的生物学定义特征。
Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14.
6
The incidence rate of female breast cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001-2008.沙特阿拉伯女性乳腺癌发病率:沙特癌症登记处 2001-2008 年数据的观察性描述性流行病学分析。
Breast Cancer (Dove Med Press). 2013 Oct 17;5:103-9. doi: 10.2147/BCTT.S50750. eCollection 2013.
7
Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.新辅助全身治疗的乳腺癌患者肿瘤浸润淋巴细胞的预测和预后意义。
Anticancer Res. 2014 Mar;34(3):1115-25.
8
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.肿瘤浸润 CD8+ 淋巴细胞是乳腺癌原发系统性治疗病理完全缓解的独立预测因素。
Br J Cancer. 2013 Nov 12;109(10):2705-13. doi: 10.1038/bjc.2013.634. Epub 2013 Oct 15.
9
Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.肿瘤相关淋巴细胞预测乳腺癌患者新辅助化疗的反应。
J Breast Cancer. 2013 Mar;16(1):32-9. doi: 10.4048/jbc.2013.16.1.32. Epub 2013 Mar 31.
10
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.免疫组化定义的 luminal A 型乳腺癌中孕激素受体阳性肿瘤细胞的预后意义。
J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.

新辅助化疗治疗的腔面B/HER 2阴性乳腺癌患者中CD8肿瘤浸润淋巴细胞的预测和预后意义

Predictive and prognostic significance of CD8 tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.

作者信息

Al-Saleh Khalid, Abd El-Aziz Nashwa, Ali Arwa, Abozeed Waleed, Abd El-Warith Ahmed, Ibraheem Ahmed, Ansari Jawaher, Al-Rikabi Ammar, Husain Sufia, Nabholtz Jean-Marc

机构信息

Division of Hematology/Oncology, Department of Medicine, King Khalid University Hospital/College of Medicine, King Saud University, Riyadh 11472 7805, Saudi Arabia.

Department of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut 71516, Egypt.

出版信息

Oncol Lett. 2017 Jul;14(1):337-344. doi: 10.3892/ol.2017.6144. Epub 2017 May 10.

DOI:10.3892/ol.2017.6144
PMID:28693173
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5494820/
Abstract

The immunobiology of breast cancer (BC) subtypes, including luminal cancer, remains unclear. Cluster of differentiation (CD)8 tumor-infiltrating lymphocytes (TIL) are essential components of tumor-specific cellular adaptive immunity. However, only few studies have addressed the significance of cluster of differentiation 8(CD8) TIL in patients with luminal BC. The present study aimed to evaluate the predictive and prognostic significance of CD8 TIL in patients with luminal B/human epidermal growth factor receptor 2 (HER 2)-negative BC treated with anthracycline-based neoadjuvant chemotherapy (NC). A total of 31 patients who underwent breast-conserving surgery or mastectomy post-NC were enrolled. Immunostaining for CD8 TIL was performed using rabbit monoclonal antibodies against human CD8. Intra- and peritumoral CD8 TIL expression levels were classified into high and low, based on the median value of each. CD8 TIL expression data were demonstrated to be correlated with disease-free survival (DFS) and overall survival (OS), using Kaplan-Meier and Cox's proportional hazards regression tests. The results revealed that, among all clinicopathological characteristics, only pathological complete response (pCR) was significantly correlated with intratumoral CD8 TIL expression (P=0.016). A total of 9/16 patients (56%) with high intratumoral CD8 TIL expression achieved pCR, in contrast with 2 out of 15 patients (13.3%) with low expression (P=0.016). High expression of intratumoral CD8 TIL was significantly associated with OS (log-rank test, P=0.023). Multivariate Cox regression analysis revealed that intratumoral expression of CD8 TIL was an independent prognostic factor for OS [hazard ratio (HR)=2.82; 95% confidence interval (CI)=0.911-4.833, P=0.007], but not for DFS (HR=1.11; 95% CI=0.282-2.078; P=0.508). In conclusion, the results of the present study suggested that high intratumoral CD8 TIL expression was significantly predictive of pCR post-NC, and represented an independent prognostic factor for improved OS. In contrast, low intratumoral CD8 TIL expression was a strong predictor of lack of pCR to NC, as well as an independent prognostic factor for poor OS. Assessment of the immune response in conjunction with the usual parameters may aid in the further stratification of patients with luminal B/HER 2-negative BC regarding the prediction of pCR post-NC and overall prognosis.

摘要

包括管腔癌在内的乳腺癌(BC)亚型的免疫生物学仍不清楚。分化簇(CD)8肿瘤浸润淋巴细胞(TIL)是肿瘤特异性细胞适应性免疫的重要组成部分。然而,仅有少数研究探讨了分化簇8(CD8)TIL在管腔型BC患者中的意义。本研究旨在评估CD8 TIL在接受蒽环类药物新辅助化疗(NC)的管腔B/人表皮生长因子受体2(HER 2)阴性BC患者中的预测和预后意义。总共纳入了31例在NC后接受保乳手术或乳房切除术的患者。使用抗人CD8兔单克隆抗体对CD8 TIL进行免疫染色。根据各自的中位数,将肿瘤内和肿瘤周围CD8 TIL表达水平分为高和低。使用Kaplan-Meier和Cox比例风险回归检验证明CD8 TIL表达数据与无病生存期(DFS)和总生存期(OS)相关。结果显示,在所有临床病理特征中,仅病理完全缓解(pCR)与肿瘤内CD8 TIL表达显著相关(P = 0.016)。肿瘤内CD8 TIL表达高的16例患者中有9例(56%)达到pCR,相比之下,表达低的15例患者中有2例(13.3%)达到pCR(P = 0.016)。肿瘤内CD8 TIL高表达与OS显著相关(对数秩检验,P = 0.023)。多变量Cox回归分析显示,肿瘤内CD8 TIL表达是OS的独立预后因素[风险比(HR)= 2.82;95%置信区间(CI)= 0.911 - 4.833,P = 0.007],但不是DFS的独立预后因素(HR = 1.11;95% CI = 0.282 - 2.078;P = 0.508)。总之,本研究结果表明,肿瘤内CD8 TIL高表达对NC后的pCR具有显著预测性,并且是OS改善的独立预后因素。相反,肿瘤内CD8 TIL低表达是NC后缺乏pCR的有力预测指标,也是OS不良的独立预后因素。结合常规参数评估免疫反应可能有助于对管腔B/HER 2阴性BC患者在预测NC后pCR和总体预后方面进行进一步分层。